Endologix and LeMaitre Vascular Enter Early Termination Agreement for European Distribution Rights of Endologix Products

Accelerates Endologix's Transition to Direct Sales in Europe Supports LeMaitre's Strategy to Focus on Core Vascular Products Endologix, Inc. ELGX and LeMaitre Vascular, Inc. LMAT announced today that the companies have entered into an early termination agreement for LeMaitre's distribution rights of Endologix's aortic endovascular products in Europe. Under the terms of the agreement, Endologix will pay LeMaitre $1.3 million to begin selling direct on September 1, 2011. Previously, LeMaitre held distribution rights in certain European countries for Endologix's Powerlink® System, and related products, through June 30, 2013. John McDermott, President and Chief Executive Officer of Endologix, commented, "This agreement allows us to accelerate our planned transition to a direct sales force in Europe and gain control of the sales channel at an important time in the development of our European business. It provides us with the opportunity to begin establishing a presence and developing physician relationships ahead of the anticipated European launch of our Nellix® Endovascular System and Ventana™ Fenestrated Stent Graft System in 2012. Both organizations are committed to a smooth transition and we would like to thank LeMaitre for their partnership over the past few years."